1 Department of Emergency, The People's Hospital of Guangxi Zhuang Autonomous Region , Nanning, China .
2 Department of Ultrasound, The People's Hospital of Guangxi Zhuang Autonomous Region , Nanning, China .
Cancer Biother Radiopharm. 2018 Feb;33(1):3-7. doi: 10.1089/cbr.2017.2287.
Gastric carcinoma is the most popular cancer worldwide. Anoctamin-1 is a calcium-activated channel and highly expressed in various tumors. A previous study indicated that suppressed Anoctamin-1 expression decreased cancer cell proliferation or migration. As a signal transduction and transcription activator, STAT6 is a novel agonist for Anoctamin-1 promoter. However, its role in tumor cell proliferation or migration remains unclear. Therefore, this study aimed to suppress STAT6 and Anoctamin-1 protein expression in gastric cancer cells to test the inhibitory effects on gastric cancer cell migration or invasion.
MTT colorimetry was used to test cell proliferation. Western blot was used to measure STAT6 and Anoctamin-1 expression before and after small interfering RNA (siRNA) treatment. A scratch assay was performed to measure cell migration, followed by Transwell chamber assay analysis of cell invasion.
After STAT6 siRNA interference, the expression of STAT6 and Anoctamin-1 was significantly decreased in the gastric carcinoma cell line. Anoctamin-1 siRNA interference only decreased its protein expression, but not STAT6 protein expression. Interference of STAT6 or Anoctamin-1 reduced their protein expression and inhibited proliferation, migration, or invasion of gastric cancer cells.
Inhibition of STAT6/Anoctamin-1 activation decreased proliferation, migration, or invasion of gastric cancer cells, suggesting that the STAT6/Anoctamin-1 pathway might be a novel target for treating gastric cancer.
胃癌是全球最常见的癌症之一。Anoctamin-1 是一种钙激活通道，在多种肿瘤中高度表达。先前的研究表明，抑制 Anoctamin-1 的表达会降低癌细胞的增殖或迁移能力。作为信号转导和转录激活因子，STAT6 是 Anoctamin-1 启动子的新型激动剂。然而，其在肿瘤细胞增殖或迁移中的作用尚不清楚。因此，本研究旨在抑制胃癌细胞中 STAT6 和 Anoctamin-1 蛋白的表达，以测试其对胃癌细胞迁移或侵袭的抑制作用。
MTT 比色法用于检测细胞增殖。Western blot 用于测量 STAT6 和 Anoctamin-1 表达在 siRNA 处理前后的变化。划痕实验用于测量细胞迁移，随后通过 Transwell 室分析细胞侵袭。
在 STAT6 siRNA 干扰后，胃癌细胞系中 STAT6 和 Anoctamin-1 的表达明显降低。Anoctamin-1 siRNA 干扰仅降低其蛋白表达，而不降低 STAT6 蛋白表达。干扰 STAT6 或 Anoctamin-1 均降低其蛋白表达，并抑制胃癌细胞的增殖、迁移或侵袭。
抑制 STAT6/Anoctamin-1 激活可降低胃癌细胞的增殖、迁移或侵袭能力，提示 STAT6/Anoctamin-1 通路可能是治疗胃癌的新靶点。
